EP4259626C0 - PROCESS FOR PREPARING 4-(3,5-DIFLUOROPHENYL)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3-AZABICYCLO[3.2.1 OCTAN-8-YL)6,7-DIHYDRO-5H-[1,2,4 TRIAZOLO[1,5-A PYRIMIDIN-2-AMIN - Google Patents

PROCESS FOR PREPARING 4-(3,5-DIFLUOROPHENYL)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3-AZABICYCLO[3.2.1 OCTAN-8-YL)6,7-DIHYDRO-5H-[1,2,4 TRIAZOLO[1,5-A PYRIMIDIN-2-AMIN

Info

Publication number
EP4259626C0
EP4259626C0 EP21835211.0A EP21835211A EP4259626C0 EP 4259626 C0 EP4259626 C0 EP 4259626C0 EP 21835211 A EP21835211 A EP 21835211A EP 4259626 C0 EP4259626 C0 EP 4259626C0
Authority
EP
European Patent Office
Prior art keywords
methylpyrimidin
octan
amin
triazolo
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP21835211.0A
Other languages
German (de)
French (fr)
Other versions
EP4259626B1 (en
EP4259626A1 (en
Inventor
Guocai Zhang
Weichun Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP4259626A1 publication Critical patent/EP4259626A1/en
Application granted granted Critical
Publication of EP4259626C0 publication Critical patent/EP4259626C0/en
Publication of EP4259626B1 publication Critical patent/EP4259626B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/04—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing carboxylic acids or their salts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21835211.0A 2020-12-10 2021-12-08 Process for the preparation 4-(3,5-difluorophenyl)-n-[3-(6-methylpyrimidin-4-yl)-3- azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine Active EP4259626B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020135294 2020-12-10
PCT/EP2021/084734 WO2022122800A1 (en) 2020-12-10 2021-12-08 Process for the preparation 4-(3,5-difluorophenyl)-n-[3-(6-methylpyrimidin-4-yl)-3- azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine

Publications (3)

Publication Number Publication Date
EP4259626A1 EP4259626A1 (en) 2023-10-18
EP4259626C0 true EP4259626C0 (en) 2025-01-29
EP4259626B1 EP4259626B1 (en) 2025-01-29

Family

ID=79171263

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21835211.0A Active EP4259626B1 (en) 2020-12-10 2021-12-08 Process for the preparation 4-(3,5-difluorophenyl)-n-[3-(6-methylpyrimidin-4-yl)-3- azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine

Country Status (13)

Country Link
US (1) US20240025911A1 (en)
EP (1) EP4259626B1 (en)
JP (1) JP7837977B2 (en)
KR (1) KR20230118099A (en)
CN (1) CN116568298A (en)
AR (1) AR124195A1 (en)
AU (1) AU2021393922A1 (en)
BR (1) BR112023011020A2 (en)
CA (1) CA3202551A1 (en)
IL (1) IL303354A (en)
MX (1) MX2023006712A (en)
TW (1) TW202237613A (en)
WO (1) WO2022122800A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
AR109829A1 (en) 2016-09-29 2019-01-30 Hoffmann La Roche BRIDGED PIPERIDINE DERIVATIVES
EP3523304B1 (en) 2016-10-04 2021-01-27 H. Hoffnabb-La Roche Ag Bicyclic heteroaryl derivatives
US11319314B2 (en) * 2016-11-08 2022-05-03 Hoffmann-La Roche Inc. Phenoxytriazoles
US11370802B2 (en) 2018-01-22 2022-06-28 Hoffmann-La Roche, Inc. Triazolo-azepine derivatives

Also Published As

Publication number Publication date
AU2021393922A9 (en) 2024-02-08
MX2023006712A (en) 2023-06-20
CN116568298A (en) 2023-08-08
KR20230118099A (en) 2023-08-10
WO2022122800A1 (en) 2022-06-16
US20240025911A1 (en) 2024-01-25
AR124195A1 (en) 2023-02-22
BR112023011020A2 (en) 2024-01-30
CA3202551A1 (en) 2022-06-16
JP2023553941A (en) 2023-12-26
TW202237613A (en) 2022-10-01
JP7837977B2 (en) 2026-03-31
EP4259626B1 (en) 2025-01-29
EP4259626A1 (en) 2023-10-18
AU2021393922A1 (en) 2023-06-15
IL303354A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
EP4206186A4 (en) Preparation method for 1,5-pentane diisocyanate
MX2011001679A (en) Flavin derivatives.
DE602006021645D1 (en) Process and intermediates for the preparation of N4-phenyl quinazoline-4-amine derivatives
EA201001238A1 (en) COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
EA200702347A1 (en) METHOD FOR OBTAINING GLUCOPYRANOSYLESE-SUBSTITUTED DERIVATIVES OF BENZILBENZENE AND INTERMEDIATE PRODUCTS FOR THEIR OBTAINING
PH12015500275A1 (en) Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
MX2012008911A (en) SALTS AND POLYMORPHES OF 8-FLUORO-2- {4 - [(METHYLAMINE) METHYL] PHENYL} -1,3, 4,5-TETRAHYDRO-6H-ACEPINO [5,4,3-CD] INDOL-6-ONA.
EA201100748A1 (en) PYRAZINE COMPOUNDS AS PHOSPHODESTERASE INHIBITORS 10
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
TW200621256A (en) Formulations
DE602007003375D1 (en) PROCESS FOR PREPARING 3 (R) - (2-HYDROXY-2,2-DITHIEN-2-YLACETOXY) -1- (3-PHENOXYPROPYL) -1-AZONIABICYCLOE2.2.2ÜOCTANBROMIDE
WO2018029711A3 (en) Process for the preparation of venetoclax
EP4317353A4 (en) POLISHING COMPOSITION, METHOD FOR PREPARING THE POLISHING COMPOSITION AND POLISHING METHOD
NO20082425L (en) Formulations comprising jorumycin, reni-eramycin, safracin or saframycin-related compounds for the treatment of proliferative diseases
EP3953339C0 (en) PROCESS FOR PREPARING 1-DEOXY-1-METHYLAMINO-D-GLUCITOL-2-(3,5-DICHLOROPHENYL)-6-BENZOXAZOLE CARBOXYLATE
MX394391B (en) Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
ATE411994T1 (en) PREPARATION OF A HIGH PURITY SUBSTITUTED QUINOXALINE
MX388697B (en) THIAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE.
TW201612169A (en) (R)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
DE602005014280D1 (en) PROCESS FOR THE PREPARATION OF Ä1,4,5Ü-OXADIAZEPINE DERIVATIVES
DE502005000428D1 (en) Process for the preparation of 1,2-diaminocyclohexane-platinum (II) complexes
TW200617011A (en) Process for preparing quinoline compounds and products obtained therefrom
DE502006004524D1 (en) PROCESS FOR THE PREPARATION OF 3,7-DIAZA BICYCLOÄ3.3.1ÜNONAN COMPOUNDS
DE60315308D1 (en) PROCESS FOR PREPARING 5- (4-FLUORPHENYL) -1-i2 - ((2R, 4R) -4-HYDROXY-6-OXOTETRAHYDROPYRAN-2-YL) ETHYLO-2-ISOPROPYL-4-PHENYL-1H-PYRROL-3 -CARBONSÄUREPHENYLAMID
EP3902790C0 (en) IMPROVED PROCESS FOR THE PREPARATION OF 4,6-DIHYDROXYPYRIMIDINE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230710

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240813

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602021025592

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20250129

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20250204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250529

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250129

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: L10

Free format text: ST27 STATUS EVENT CODE: U-0-0-L10-L00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251210

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 5

Effective date: 20251119

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260101

26N No opposition filed

Effective date: 20251030

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251119

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20260101

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250129

U1H Name or address of the proprietor changed after the registration of the unitary effect

Owner name: F. HOFFMANN-LA ROCHE AG; CH